Atezolizumab and Bevacizumab in Hepatocellular Carcinoma

被引：20

作者：

Bomze, David ^{[1
]}

Meirson, Tomer ^{[2
]}

Azoulay, Daniel ^{[2
]}

机构：

[1] Ankara City Hosp, Ankara, Turkey

[2] Yildirim Beyazit Univ, Ankara, Turkey

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 383卷 / 07期

关键词：

D O I：

10.1056/NEJMc2021840

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：693 / 694

页数：2

共 5 条

[1] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

[2] Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma [J].

Kudo, Masatoshi .

CANCERS, 2020, 12 (05)

[3] A note on quantifying follow-up in studies of failure time [J].

Schemper, M ;

Smith, TL .

CONTROLLED CLINICAL TRIALS, 1996, 17 (04) :343-346

[4] Reconstructing time-to-event data from published Kaplan-Meier curves [J].

Wei, Yinghui ;

Royston, Patrick .

STATA JOURNAL, 2017, 17 (04) :786-801

[5]

Yau T, 2019, ANN ONCOL, V30, P874

← 1 →